• Bafilomycin A1: Evidence, Scope, and Limits

  2026-10-12

  Bafilomycin A1 is described by APExBIO as a reversible V-ATPase inhibitor relevant to studies of organellar acidification, intracellular pH regulation, and lysosomal function. The supplied acute lymphoblastic leukemia study provides important evidence that microtubule depolymerization can trigger distinct cell-death programs in G1 and M phases, but it does not directly test Bafilomycin A1 or establish a V-ATPase-dependent mechanism. These findings therefore support a conceptual connection to autophagy and lysosomal biology, not a direct claim about Bafilomycin A1 in leukemia.

• Shionone, Mitophagy and Pulmonary Fibrosis

  2026-10-12

  A 2026 preclinical study links shionone with reduced pulmonary-fibrosis features through PINK1–Parkin-associated mitophagy. The findings are mechanistically suggestive but remain limited by model choice, assay interpretation, and the absence of clinical evidence.

• PLAC1 in ccRCC: Promise and Evidence Limits

  2026-10-11

  A source-grounded overview of PLAC1 as a proposed clear cell renal cell carcinoma biomarker and molecular target, distinguishing the findings of Kong et al. from broader claims about compound libraries and therapeutic applicability.

• Gastrin I in Organoid and GI Research

  2026-10-10

  A source-grounded overview of Gastrin I, its proposed relevance to gastric acid secretion pathway research, and how its evidence base compares with recent human pluripotent stem cell-derived intestinal organoid research.

• Enzyme and Transporter DDI Risk in 2022 FDA Drugs

  2026-10-09

  Yu, Wang, and Ragueneau-Majlessi provide an integrated analysis of enzyme- and transporter-mediated drug interactions identified in FDA reviews of 22 small-molecule drugs approved in 2022. The study links mechanistic in vitro, model-based, and clinical evidence to labeling decisions, with Oteseconazole identified as a clinical inhibitor of P-glycoprotein and/or BCRP.

• Resiniferatoxin (RTX): From TRPV1 to Translation

  2026-10-09

  Resiniferatoxin (RTX) offers a distinctive translational strategy: use highly selective TRPV1 activation to produce sustained desensitization of pain-sensing afferents. This thought-leadership analysis connects receptor biology, validation strategy, competitive positioning, clinical evidence, and the decisions that will determine whether RTX becomes a durable precision analgesic.

• Resiniferatoxin (RTX): TRPV1 Evidence Guide

  2026-10-08

  Resiniferatoxin (RTX) is an ultra-potent TRPV1 agonist used to study calcium-dependent sensory-neuron desensitization and pain biology. A 2025 mouse study shows that cyclodextrin-mediated cholesterol depletion can reduce selected RTX-associated pain endpoints, but the findings do not establish clinical efficacy for RTX or cyclodextrins.

• Oteseconazole: Research Context and Evidence

  2026-10-08

  Oteseconazole (VT-1161) is a tetrazole CYP51 inhibitor being studied in the broader context of antifungal resistance and Candida disease. This overview separates findings from interpretation, compares the available Candida auris evidence with broader translational applications, and highlights important limits in the supplied literature.

• Intra-articular Resiniferatoxin for OA Pain

  2026-10-07

  The 2025 review evaluates intra-articular Resiniferatoxin (RTX) as a peripheral TRPV1-targeting approach to osteoarthritic pain. Its central contribution is a translational synthesis linking cellular mechanisms, animal studies, canine evidence, and preliminary human investigations while emphasizing that clinical efficacy and long-term safety remain incompletely established.

• Sitagliptin and Intestinal Stretch Signaling

  2026-10-07

  Sitagliptin phosphate monohydrate offers a precise lens for studying DPP-4-dependent incretin biology. This article examines how chemical incretin modulation differs from intestinal stretch signaling and why that distinction matters in metabolic research.

• MitMAB and Milk EV Uptake Research

  2026-10-06

  A source-grounded overview of MitMAB, dynamin-related endocytosis research, and the reported uptake of milk-derived extracellular vesicles in porcine intestinal stem cell models. The evidence supports polarity- and region-dependent uptake, but does not establish that MitMAB was used in the cited study or that dynamin is the sole mechanism involved.

• Gastrin I: Translating Organoid Evidence

  2026-10-06

  Gastrin I research gains value when gastric receptor biology is interpreted alongside human intestinal organoid evidence. This article separates established mechanisms from emerging model applications and defines how human Gastrin I peptide studies can support gastrointestinal physiology research without overextending pharmacokinetic findings.

• Gastrin I in Human GI Research: Evidence and Limits

  2026-10-05

  Gastrin I is relevant to research on CCK2-linked gastric signaling and acid secretion, but the supplied organoid study does not directly test the peptide. This overview separates supplier-described biology from peer-reviewed findings on hiPSC-derived intestinal organoids, clarifies conceptual applications, and defines the limits of translating intestinal pharmacokinetic models into gastric physiology or therapeutic claims.

• TRPV1 Modulation in Metastatic Breast Cancer

  2026-10-05

  This 2021 Life Sciences study examined how TRPV1 modulation alters cytokine responses in mice bearing distinct metastatic breast carcinoma subtypes. Its central finding is that TRPV1 agonism produced different, and sometimes adverse, immune effects in tumor-bearing versus control animals, highlighting the importance of disease context when interpreting TRPV1 pharmacology.

• Berberine and Evodiamine Modulate GERD via TRPV1

  2026-10-04

  A 2024 Phytomedicine study reports that berberine and evodiamine reduced esophageal injury and inflammatory responses in rat and cell models of gastroesophageal reflux disease. Its main innovation is a mechanistic framework linking TAS2R38 and TRPV1 to MAPK/NF-κB signaling, epithelial barrier preservation, and macrophage-polarization changes.

7849 records 1/524 page Next 12345 下5页 Last page